Market Overview

Study Shows Gilead's Ranexa Reduces Angina Frequency in Chronic Angina Patients With Type 2 Diabetes


Gilead Sciences (NASDAQ: GILD) today announced data from the Phase
4 TERISA (Type 2 Diabetes Evaluation
of Ranolazine In
Subjects With Chronic Stable Angina)
study, which demonstrated that the addition of ranolazine to background
antianginal therapy in chronic angina patients with type 2 diabetes
significantly reduced the frequency of weekly angina episodes compared
to placebo and background antianginal therapy. Results were presented
today during a Late-Breaking Clinical Trial session at the American
College of Cardiology's 62nd Annual Scientific Session
(ACC.13) in San Francisco and were published online ahead of print in
the Journal of the American College of Cardiology.

Ranexa® (ranolazine) is indicated for the treatment of

See full press release

Posted-In: News Guidance Management M&A


Related Articles (GILD)

View Comments and Join the Discussion!

Partner Center